Document is current

Article History

Accepted: 1 May 2024

First Online: 20 May 2024

Declarations

:

: Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo (VMT, AHS) and the Cummings Foundation (VMT, AHS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

: BAS: None. KEP: None. S-SKC: None. JL: None. AAB: None. VJ: None. KPR: None. TRP: Grant Support: Brain Aneurysm Foundation. MS: None. EIL: Board Membership: Stryker, NeXtGen Biologics, MedX Health, Cognition Medical, EndoStream; Consultancy: Claret Medical, GLG Consulting, Guidepoint, Imperative Care, Medtronic, Rebound Therapeutics, StimMed; Employment: University at Buffalo Neurosurgery Inc; Expert Testimony: renders medical/legal opinions as an expert witness; Stock/Stock Options: NeXtGen Biologics, Cognition Medical, Rapid Medical, Claret Medical, Imperative Care, Rebound Therapeutics, StimMed. AHS: Financial Interest/Investor/Stock Options/Ownership: Adona Medical, Inc., Amnis Therapeutics, Bend IT Technologies, Ltd., BlinkTBI, Inc, Buffalo Technology Partners, Inc., Cardinal Consultants, LLC, Cerebrotech Medical Systems, Inc, Cerevatech Medical, Inc., Cognition Medical, CVAID Ltd., Endostream Medical, Ltd, Imperative Care, Inc., Instylla, Inc., International Medical Distribution Partners, Launch NY, Inc., NeuroRadial Technologies, Inc., Neurotechnology Investors, Neurovascular Diagnostics, Inc., PerFlow Medical, Ltd., Q’Apel Medical, Inc., QAS.ai, Inc., Radical Catheter Technologies, Inc., Rebound Therapeutics Corp. (Purchased 2019 by Integra Lifesciences, Corp), Rist Neurovascular, Inc. (Purchased 2020 by Medtronic), Sense Diagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, SongBird Therapy, Spinnaker Medical, Inc., StimMed, LLC, Synchron, Inc., Three Rivers Medical, Inc., Truvic Medical, Inc., Tulavi Therapeutics, Inc., Vastrax, LLC, VICIS, Inc., Viseon, Inc. Consultant/Advisory Board: ational Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo. VMT: Financial Interest/Investor/Stock Options/Ownership: Neurovascular Diagnostics, Inc., QAS.ai, Inc. Grant Support: Brain Aneurysm Foundation, National Science Foundation Award No. 1746694, NIH NINDS award R43 NS115314-0, clinical and translational science institute grant from the national Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo. Consultant/Advisory Board: Canon Medical Systems America.

: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Human Research Institutional Review Board of the University at Buffalo (study number STUDY00002092). Informed consent was obtained from all subjects involved in the study and the study was carried out in accordance with the approved protocols.

: No specific patient information or images are given in the article.

: The datasets used in the current study are available from the corresponding author upon reasonable request.

: Not applicable. All codes are publicly available, as references in the article.

: Conceptualization, BAS, VMT; methodology, BAS, VMT; software, KEP, VMT.; validation, K.E.P., L.C., and V.M.T.; formal analysis, BAS, KEP, SSKC, VMT; investigation, BAS, EIL, AHS, VMT; resources, EIL, AHS, VMT; data curation, AAB, KPR, TRP, MS, EIL, AHS, VMT; writing—original draft preparation, BAS, KEP, VMT; writing—review and editing, all authors; visualization, BAS, VMT; supervision, AHS, VMT; project administration, VMT; funding acquisition, AHS, VMT. All authors have read and agreed to the published version of the article.